NCT03883074View on ClinicalTrials.gov

Effect of a Combination of Hyaluronic Acid, Chondroitin Sulphate and Magnesium Trisilicate on Subjects With GastroEsophageal Reflux Disease

NACompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 20, 2018

Primary Completion Date

September 16, 2021

Study Completion Date

September 16, 2021

Conditions
Gastro Esophageal Reflux
Interventions
DEVICE

hyaluronic acid with chondroitin + sulphate + magnesium trisilicate

Melt in mouth tablets (1100 mg)

DEVICE

Placebo

tablets with the same aspect of the active device

Trial Locations (1)

box 701, 3000

UZLeuven, Leuven

All Listed Sponsors
lead

SOFAR S.p.A.

INDUSTRY

NCT03883074 - Effect of a Combination of Hyaluronic Acid, Chondroitin Sulphate and Magnesium Trisilicate on Subjects With GastroEsophageal Reflux Disease | Biotech Hunter | Biotech Hunter